论文部分内容阅读
格替沙星(gatifloxacin,GFLX,AM—1155)是日本杏林制药公司首先研究和开发的新的高效广谱喹诺酮类抗菌药。日本多家医院及研究机构的临床研究表明,此药物可应用于呼吸系统感染、泌尿系统感染、生殖系统感染以及医院多科如皮肤科、耳鼻喉科、眼科、外科、牙科及口腔外科感染等。 1、呼吸系统感染 GFLX对治疗肺炎(细菌的,支原体的和衣原体的肺炎)、慢性气管炎、支气管扩张、慢性肺结核病疗效较佳。 GFLX与左氧氟沙星(levofloxacin,LVFX)对肺炎(细菌的,支原体的和衣原体的肺炎)的双盲研究,比较二者对肺炎
Gatifloxacin (GFLX, AM-1155) is the first highly effective broad-spectrum quinolone antibacterial drug researched and developed by Japan’s Xinglin Pharmaceutical Company. Clinical research in hospitals and research institutes in Japan shows that this medicine can be applied to respiratory infections, urinary tract infections, reproductive system infections and many hospital departments such as dermatology, otolaryngology, ophthalmology, surgery, dentistry and oral surgery infections . 1, respiratory infections GFLX treatment of pneumonia (bacterial, mycoplasma and chlamydia pneumonia), chronic bronchitis, bronchiectasis, chronic tuberculosis better curative effect. A double-blind study of pneumonia (bacterial, mycoplasmal, and chlamydial pneumonia) with GFLX and levofloxacin (LVFX) compared pneumonia